Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Levy

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Annals of the American Thoracic Society|December 25, 2013
Executive summary: Developing a new, national approach to surveillance for ventilator-associated eventsShelley S Magill, Michael Klompas, Robert Balk, et al.
Critical Care Medicine|October 29, 2013
Developing a new, national approach to surveillance for ventilator-associated events*Shelley S Magill, Michael Klompas, Robert Balk, et al.
Infection Control and Hospital Epidemiology|November 15, 2013
Developing a new, national approach to surveillance for ventilator-associated events: executive summaryShelley S Magill, Michael Klompas, Robert Balk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2013
Developing a new, national approach to surveillance for ventilator-associated events: executive summaryShelley S Magill, Michael Klompas, Robert Balk, et al.
Eclinicalmedicine|June 23, 2023
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trialBruno François, Simon Lambden, Jean-Jacques Garaud, et al.
The Lancet. Respiratory Medicine|June 3, 2023
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Simon Lambden, Tom Fivez, et al.
Journal of Intensive Care|March 5, 2019
Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohortBert K Lopansri, Russell R Miller Iii, John P Burke, et al.
Journal of Clinical Medicine|April 9, 2024
Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic InflammationRobert Balk, Annette M Esper, Greg S Martin, et al.
Journal of Clinical Medicine|October 26, 2024
Rapid and Robust Identification of Sepsis Using SeptiCyte RAPID in a Heterogeneous Patient PopulationRobert Balk, Annette M Esper, Greg S Martin, et al.
American Journal of Respiratory and Critical Care Medicine|April 7, 2018
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICURussell R Miller, Bert K Lopansri, John P Burke, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Annals of the American Thoracic Society|December 25, 2013
Executive summary: Developing a new, national approach to surveillance for ventilator-associated eventsShelley S Magill, Michael Klompas, Robert Balk, et al.
Critical Care Medicine|October 29, 2013
Developing a new, national approach to surveillance for ventilator-associated events*Shelley S Magill, Michael Klompas, Robert Balk, et al.
Infection Control and Hospital Epidemiology|November 15, 2013
Developing a new, national approach to surveillance for ventilator-associated events: executive summaryShelley S Magill, Michael Klompas, Robert Balk, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2013
Developing a new, national approach to surveillance for ventilator-associated events: executive summaryShelley S Magill, Michael Klompas, Robert Balk, et al.
Eclinicalmedicine|June 23, 2023
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trialBruno François, Simon Lambden, Jean-Jacques Garaud, et al.
The Lancet. Respiratory Medicine|June 3, 2023
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trialBruno François, Simon Lambden, Tom Fivez, et al.
Journal of Intensive Care|March 5, 2019
Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohortBert K Lopansri, Russell R Miller Iii, John P Burke, et al.
Journal of Clinical Medicine|April 9, 2024
Validation of SeptiCyte RAPID to Discriminate Sepsis from Non-Infectious Systemic InflammationRobert Balk, Annette M Esper, Greg S Martin, et al.
Journal of Clinical Medicine|October 26, 2024
Rapid and Robust Identification of Sepsis Using SeptiCyte RAPID in a Heterogeneous Patient PopulationRobert Balk, Annette M Esper, Greg S Martin, et al.
American Journal of Respiratory and Critical Care Medicine|April 7, 2018
Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICURussell R Miller, Bert K Lopansri, John P Burke, et al.
Pageof 7